Bortezomib maintenance after R‐CHOP, cytarabine and autologous stem cell transplantation in newly diagnosed patients with mantle cell lymphoma, results of a randomised phase II HOVON trial

Rituximab‐containing induction followed by autologous stem cell transplantation (ASCT) is the standard first‐line treatment for young mantle cell lymphoma patients. However, most patients relapse after ASCT. We investigated in a randomised phase II study the outcome of a chemo‐immuno regimen and ASC...

Descripción completa

Detalles Bibliográficos
Autores principales: Doorduijn, Jeanette K., Zijlstra, Josee M., Lugtenburg, Pieternella J., Kersten, Marie Josee, Böhmer, Lara H., Minnema, Monique C., MacKenzie, Marius A., van Marwijk Kooij, Rien, de Jongh, Eva, Snijders, Tjeerd J.F., de Weerdt, Okke, van Gelder, Michel, Hoogendoorn, Mels, Leys, Rineke B.L., Kibbelaar, Robby E., de Jong, Daphne, Chitu, Dana A., Van’t Veer, Mars B., Kluin‐Nelemans, Hanneke C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Haematological Malignancy ‐ Clinical
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7496560/
https://www.ncbi.nlm.nih.gov/pubmed/32150297
http://dx.doi.org/10.1111/bjh.16567

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7496560/
https://www.ncbi.nlm.nih.gov/pubmed/32150297
http://dx.doi.org/10.1111/bjh.16567

Ejemplares similares